Market Closed -
Euronext Bruxelles
11:35:26 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.216
EUR
|
-1.82%
|
|
-.--%
|
-82.78%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
752.8
|
989.7
|
841.5
|
880.1
|
186.5
|
14.93
|
14.93
|
-
|
Enterprise Value (EV)
1 |
721
|
1,138
|
1,008
|
1,201
|
486.3
|
396.8
|
181.4
|
227.7
|
P/E ratio
|
-60.6
x
|
-37.5
x
|
-8.76
x
|
-7.43
x
|
-2.79
x
|
-0.16
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.5
x
|
10.3
x
|
93.2
x
|
38.8
x
|
2.78
x
|
2.16
x
|
0.34
x
|
0.27
x
|
EV / Revenue
|
11
x
|
11.8
x
|
112
x
|
53
x
|
7.26
x
|
9.88
x
|
4.13
x
|
4.1
x
|
EV / EBITDA
|
18.8
x
|
35.8
x
|
-13.7
x
|
-15.5
x
|
-34
x
|
-7.52
x
|
-6.13
x
|
6.78
x
|
EV / FCF
|
-111
x
|
-19.6
x
|
-11.1
x
|
-14
x
|
-5.9
x
|
-26.9
x
|
-7
x
|
4.55
x
|
FCF Yield
|
-0.9%
|
-5.09%
|
-9%
|
-7.15%
|
-17%
|
-3.72%
|
-14.3%
|
22%
|
Price to Book
|
4.99
x
|
6.29
x
|
5.33
x
|
25.6
x
|
5.69
x
|
0.44
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,639
|
37,689
|
42,714
|
44,051
|
54,764
|
69,108
|
69,108
|
-
|
Reference price
2 |
20.00
|
26.26
|
19.70
|
19.98
|
3.405
|
0.2160
|
0.2160
|
0.2160
|
Announcement Date
|
3/1/19
|
3/9/20
|
3/9/21
|
3/8/22
|
3/7/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
65.46
|
96.5
|
9.03
|
22.67
|
67
|
40.16
|
43.9
|
55.5
|
EBITDA
1 |
38.31
|
31.82
|
-73.81
|
-77.45
|
-14.3
|
-52.77
|
-29.6
|
33.6
|
EBIT
1 |
35.46
|
34.97
|
-79.94
|
-87.88
|
-26.24
|
-139.1
|
-47.7
|
-28
|
Operating Margin
|
54.16%
|
36.24%
|
-885.32%
|
-387.66%
|
-39.17%
|
-346.49%
|
-108.66%
|
-50.45%
|
Earnings before Tax (EBT)
1 |
-16.23
|
-40.35
|
-110.9
|
-123.8
|
-11.48
|
-161.8
|
-
|
-
|
Net income
1 |
-12.36
|
-26.6
|
-92.09
|
-116.9
|
-59.62
|
-173.5
|
-55.4
|
-8.7
|
Net margin
|
-18.88%
|
-27.56%
|
-1,019.78%
|
-515.59%
|
-88.99%
|
-432.08%
|
-126.2%
|
-15.68%
|
EPS
2 |
-0.3300
|
-0.7000
|
-2.250
|
-2.690
|
-1.220
|
-1.390
|
-
|
-
|
Free Cash Flow
1 |
-6.467
|
-57.94
|
-90.67
|
-85.87
|
-82.48
|
-9.4
|
-25.9
|
50.1
|
FCF margin
|
-9.88%
|
-60.05%
|
-1,004.1%
|
-378.82%
|
-123.11%
|
-25.79%
|
-59%
|
90.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
149.11%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/19
|
3/9/20
|
3/9/21
|
3/8/22
|
3/7/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
---|
Net sales
1 |
7.035
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
-50.47
|
Net margin
|
-717.4%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
9/26/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
149
|
167
|
321
|
300
|
310
|
167
|
213
|
Net Cash position
1 |
31.8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
4.671
x
|
-2.256
x
|
-4.141
x
|
-20.96
x
|
-5.876
x
|
-5.625
x
|
6.333
x
|
Free Cash Flow
1 |
-6.47
|
-57.9
|
-90.7
|
-85.9
|
-82.5
|
-9.4
|
-25.9
|
50.1
|
ROE (net income / shareholders' equity)
|
-10.4%
|
10.1%
|
-43.5%
|
-96.8%
|
-177%
|
-6,827%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.010
|
4.170
|
3.690
|
0.7800
|
0.6000
|
0.4900
|
-
|
-
|
Cash Flow per Share
2 |
0.0900
|
-1.240
|
-1.950
|
-1.710
|
-1.160
|
-0.2000
|
-0.4000
|
-0.3000
|
Capex
1 |
10
|
11.1
|
10.6
|
11.5
|
25.7
|
9.4
|
9.4
|
9.4
|
Capex / Sales
|
15.29%
|
11.52%
|
117.88%
|
50.66%
|
38.3%
|
25.79%
|
21.41%
|
16.94%
|
Announcement Date
|
3/1/19
|
3/9/20
|
3/9/21
|
3/8/22
|
3/7/23
|
3/8/24
|
-
|
-
|
Last Close Price
0.216
EUR Average target price
0.05
EUR Spread / Average Target -76.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -82.78% | 16.08M | | -3.79% | 88.14B | | +1.45% | 40.51B | | -15.94% | 31.67B | | +52.66% | 24.62B | | -14.50% | 15.65B | | -9.12% | 11.97B | | -14.38% | 12.07B | | -42.56% | 11.61B | | +4.87% | 8.81B |
Biopharmaceuticals
|